Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis

Devi, Rekha; Jain, Ankit; Hurkat, Pooja; Jain, Sanjay

doi:10.1007/s11095-015-1677-3

Cited by 16 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the EE% of DAG in ILPs decreased by approximately 14% compared to the LPs, which was only about 44:3 ± 1:1% and may be due to the modification process. Similar results reported by Manjappa et al [37], Devi et al [38], and Peres-Filho et al [39] showed that the encapsulation efficiency of cargoes in liposomal formulations was reduced by 5%, 10%-12%, and 16%, respectively, after modification with anti-neuropilin-1, lactic acid, and folic acid, respectively. Furthermore, the determined loading molar ratio between EMO and DAG was 1 : 3.7 and 1: 2.7 in the prepared LPs and ILPs, respectively, which was consistent with the designed radiometric of EMO and DAG for synergistic effects (Figures S1 and S2).…”

Section: Resultssupporting

confidence: 84%

Codelivery of Emodin and Diammonium Glycyrrhizinate by Anti-alpha8 Integrin-Conjugated Immunoliposomes for the Treatment of Renal Fibrosis

Sun

Yao

Luo

et al. 2020

Journal of Nanomaterials

View full text Add to dashboard Cite

The targeted delivery of therapeutics to the kidneys has a profound potential for the management of renal fibrosis. Thus, we developed a drug delivery system that targets mesangial cells by conjugating anti-alpha8 integrin to the surface of liposomes. We coloaded emodin (EMO) and diammonium glycyrrhizinate (DAG) to the immunoliposomes for combined therapy. The coloaded immunoliposomes were small size (92.4±0.4 nm), narrowly distributed, and with nearly neutral zeta potential and good stability. The encapsulation rate of EMO and DAG in immunoliposomes was 45.5±2.0% and 44.3±1.1%, respectively. Using a BCA assay, the actual number of antibody molecules attached to a single liposome was determined as being approximately 41. An in vitro release study showed that EMO and DAG could be ratiometrically released from the immunoliposomes, which means that an optimized synergistic ratio of the two drugs could be achieved. Studies on cellular uptake studies demonstrated an approximately 3-fold increase for immunoliposomes in HBZY-1 cells compared to nonconjugated liposomes. In vitro cell growth inhibition and Western Blot assay revealed that the coloaded immunoliposomes exhibited a stronger and synergistic in vitro antifibrosis effect against NIH3T3 and HBZY-1 cells in vitro. Taken together, it indicated that anti-alpha8 integrin-modified immunoliposomes for codelivery of EMO and DAG have great potential for targeting the kidneys for the treatment of renal fibrosis.

show abstract

Section: Resultssupporting

confidence: 84%

Codelivery of Emodin and Diammonium Glycyrrhizinate by Anti-alpha8 Integrin-Conjugated Immunoliposomes for the Treatment of Renal Fibrosis

Sun

Yao

Luo

et al. 2020

Journal of Nanomaterials

View full text Add to dashboard Cite

show abstract

“…1 ml of SLN suspension free from unentrapped drug was placed in dialysis tube, which was suspended in a 200ml of PBS, pH 7.4 and placed on magnetic stirrer at the temperature of 37 ± 2 ° C with continuous stirring at moderate speed (dialysis membrane/ diffusion method). At specified time intervals i.e 0.5hr, 1 hr, 2 hr, 4hr, 6hr, 12hr and 24hr, the 5 ml of samples were collected and analysed by spectrophotometrically at λmax 269nm [16].…”

Section: In-vitro Drug Release Studiesmentioning

confidence: 99%

Surface Modification of Optimized Asenapine Maleate Loaded Solid Lipid Nanoparticles Using Box-Behnken Design

Devi

Vidyavathi

Suryateja³

2021

JPRI

View full text Add to dashboard Cite

Aim: The aim of the present study was to design and evaluate solid lipid nanoparticles of Asenapine maleate (<2% bioavailability) to enhance its oral bioavailability and surface modification for brain targeting. Methods: A modified solvent injection method was used to produce Asenapine maleate loaded solid lipid nanoparticles. A RSM 3-factor, 3-level Box-Behnken design was applied to study the effect of three independent variables, concentrations of lipid (A), drug (B) and surfactant (C) on three dependent variables, particles size (Y1), entrapment efficiency (Y2), and drug release (Y3). 3-D surface response plots were drawn and optimized formulation was selected based on desirability factor. Then it was coated with tween 80 for ease of permeability through blood brain barrier due to intact absorption of solid lipid nanoparticles. Results: The results of coated optimized formulation showed average particle size of 108.9 nm, entrapment efficiency of 78.62%, and in vitro drug release of 98.88±0.102% at 36 hr at pH 7.4. Morphologically, particles were almost spherical in shape with uniform size distribution. Targeting of coated optimized formulation to brain after oral administration was confirmed by fluorescence microscopy studies on male albino wistar strain rats. This research also envisaged that there is a >85% cell viability up to 125µg/ ml concentration of coated solid lipid nanoparticles by MTT assay. Conclusion: Thus, the current study successfully designed, developed an optimized SLN formulation of Asenapine maleate using a 3-factor, 3-level Box-Behnken design for brain targeting to treat Schizophrenia by bypassing the first pass metabolism with enhanced oral bioavailability.

show abstract

“…In recent years, SLNs open new perspectives in nanomedicines. There have been major efforts to develop SLNs systems that are able to improve the drug release profiles and increase the effectiveness of the formulations for the effective control of drug delivery systems [64][65][66]. Also, Muller et al have developed ideas about drug release of SLNs [67][68][69].…”

Section: Drug Releasementioning

confidence: 99%

An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles

Khezri

Saeedi

Morteza‐Semnani

et al. 2020

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis

Abstract: The overall study paved the potential advances in brain targeting with synergistic acting drugs for effective management of NCC.

Cited by 16 publications

References 38 publications

Codelivery of Emodin and Diammonium Glycyrrhizinate by Anti-alpha8 Integrin-Conjugated Immunoliposomes for the Treatment of Renal Fibrosis

Codelivery of Emodin and Diammonium Glycyrrhizinate by Anti-alpha8 Integrin-Conjugated Immunoliposomes for the Treatment of Renal Fibrosis

Surface Modification of Optimized Asenapine Maleate Loaded Solid Lipid Nanoparticles Using Box-Behnken Design

An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles

Contact Info

Product

Resources

About